LXRX
Lexicon Pharmaceuticals Inc
NASDAQ: LXRX · HEALTHCARE · BIOTECHNOLOGY
$1.49
+0.34% today
Updated 2026-10-28
Market cap
$631.84M
P/E ratio
—
P/S ratio
15.24x
EPS (TTM)
$-0.16
Dividend yield
—
52W range
$1 – $3
Volume
2.7M
Lexicon Pharmaceuticals Inc (LXRX) Insider transactions
Net insider activity
Net buying (52,378,666 shares)
Buy transactions
68
Sell transactions
32
All transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-06-03 | SWAIN, JUDITH L | Director | Sale | 89,312 | — | — |
| 2026-06-03 | SWAIN, JUDITH L | Director | Buy | 89,312 | — | — |
| 2026-06-03 | SULLIVAN, DIANE E. | Director | Sale | 89,312 | — | — |
| 2026-06-03 | SULLIVAN, DIANE E. | Director | Buy | 89,312 | — | — |
| 2026-06-03 | SOBECKI, CHRISTOPHER J | Director | Sale | 89,312 | — | — |
| 2026-06-03 | SOBECKI, CHRISTOPHER J | Director | Buy | 89,312 | — | — |
| 2026-06-03 | DEBBANE, RAYMOND | Director | Sale | 89,312 | — | — |
| 2026-06-03 | DEBBANE, RAYMOND | Director | Buy | 89,312 | — | — |
| 2026-06-03 | CHEUNG, IVAN | Director | Sale | 89,312 | — | — |
| 2026-06-03 | CHEUNG, IVAN | Director | Buy | 89,312 | — | — |
| 2026-06-03 | BARKER, SAM L | Director | Sale | 89,312 | — | — |
| 2026-06-03 | BARKER, SAM L | Director | Buy | 89,312 | — | — |
| 2026-06-03 | AMOUYAL, PHILIPPE | Director | Sale | 89,312 | — | — |
| 2026-06-03 | AMOUYAL, PHILIPPE | Director | Buy | 89,312 | — | — |
| 2026-05-01 | SWAIN, JUDITH L | Director | Buy | 43,478 | — | — |
| 2026-05-01 | SWAIN, JUDITH L | Director | Buy | 35,714 | — | — |
| 2026-05-01 | SULLIVAN, DIANE E. | Director | Buy | 43,478 | — | — |
| 2026-05-01 | SULLIVAN, DIANE E. | Director | Buy | 35,714 | — | — |
| 2026-05-01 | SOBECKI, CHRISTOPHER J | Director | Buy | 43,478 | — | — |
| 2026-05-01 | SOBECKI, CHRISTOPHER J | Director | Buy | 35,714 | — | — |
| 2026-05-01 | DEBBANE, RAYMOND | Director | Buy | 43,478 | — | — |
| 2026-05-01 | DEBBANE, RAYMOND | Director | Buy | 35,714 | — | — |
| 2026-05-01 | CHEUNG, IVAN | Director | Buy | 43,478 | — | — |
| 2026-05-01 | CHEUNG, IVAN | Director | Buy | 35,714 | — | — |
| 2026-05-01 | BARKER, SAM L | Director | Buy | 43,478 | — | — |
| 2026-05-01 | BARKER, SAM L | Director | Buy | 35,714 | — | — |
| 2026-05-01 | AMOUYAL, PHILIPPE | Director | Buy | 43,478 | — | — |
| 2026-05-01 | AMOUYAL, PHILIPPE | Director | Buy | 35,714 | — | — |
| 2026-04-30 | ARTAL, PARTICIPATIONS S.A R.L. | Director, 10% Owner | Buy | 408,435 | — | — |
| 2026-04-30 | ARTAL, PARTICIPATIONS S.A R.L. | Director, 10% Owner | Buy | 20,421,735 | — | — |
| 2026-02-28 | MCDERMOTT, WENDY | SVP, Human Resources | Sale | 144,393 | — | — |
| 2026-02-28 | MCDERMOTT, WENDY | SVP, Human Resources | Sale | 52,316 | — | — |
| 2026-02-28 | MCDERMOTT, WENDY | SVP, Human Resources | Sale | 27,697 | — | — |
| 2026-02-28 | MCDERMOTT, WENDY | SVP, Human Resources | Buy | 144,393 | — | — |
| 2026-02-28 | MCDERMOTT, WENDY | SVP, Human Resources | Sale | 68,107 | $1.47 | $100117.29 |
| 2026-02-28 | MCDERMOTT, WENDY | SVP, Human Resources | Buy | 52,316 | — | — |
| 2026-02-28 | MCDERMOTT, WENDY | SVP, Human Resources | Buy | 27,697 | — | — |
| 2026-02-28 | MARTENS, RACHEL YAP | SVP, Partnerships & Corp Strat | Sale | 67,090 | — | — |
| 2026-02-28 | MARTENS, RACHEL YAP | SVP, Partnerships & Corp Strat | Buy | 67,090 | — | — |
| 2026-02-28 | MARTENS, RACHEL YAP | SVP, Partnerships & Corp Strat | Sale | 35,826 | $1.47 | $52664.22 |
| 2026-02-28 | GRANOWITZ, CRAIG B | SVP, Chief Medical Officer | Sale | 202,260 | — | — |
| 2026-02-28 | GRANOWITZ, CRAIG B | SVP, Chief Medical Officer | Sale | 74,226 | — | — |
| 2026-02-28 | GRANOWITZ, CRAIG B | SVP, Chief Medical Officer | Sale | 35,790 | — | — |
| 2026-02-28 | GRANOWITZ, CRAIG B | SVP, Chief Medical Officer | Buy | 202,260 | — | — |
| 2026-02-28 | GRANOWITZ, CRAIG B | SVP, Chief Medical Officer | Sale | 109,098 | $1.47 | $160374.06 |
| 2026-02-28 | GRANOWITZ, CRAIG B | SVP, Chief Medical Officer | Buy | 74,226 | — | — |
| 2026-02-28 | GRANOWITZ, CRAIG B | SVP, Chief Medical Officer | Buy | 35,790 | — | — |
| 2026-02-28 | GOPINATHAN, SUMA | SVP, Discovery | Sale | 65,640 | — | — |
| 2026-02-28 | GOPINATHAN, SUMA | SVP, Discovery | Sale | 20,310 | — | — |
| 2026-02-28 | GOPINATHAN, SUMA | SVP, Discovery | Sale | 14,000 | — | — |
| 2026-02-28 | GOPINATHAN, SUMA | SVP, Discovery | Buy | 65,640 | — | — |
| 2026-02-28 | GOPINATHAN, SUMA | SVP, Discovery | Sale | 24,338 | $1.47 | $35776.86 |
| 2026-02-28 | GOPINATHAN, SUMA | SVP, Discovery | Buy | 20,310 | — | — |
| 2026-02-28 | GOPINATHAN, SUMA | SVP, Discovery | Buy | 14,000 | — | — |
| 2026-02-28 | EXTON, MICHAEL | Director, Chief Executive Officer | Sale | 503,263 | — | — |
| 2026-02-28 | EXTON, MICHAEL | Director, Chief Executive Officer | Buy | 503,263 | — | — |
| 2026-02-28 | EXTON, MICHAEL | Director, Chief Executive Officer | Sale | 204,831 | $1.47 | $301101.57 |
| 2026-02-28 | DEFRANCESCO, LISA | SVP, IR and Corp Comm | Sale | 128,190 | — | — |
| 2026-02-28 | DEFRANCESCO, LISA | SVP, IR and Corp Comm | Sale | 24,674 | — | — |
| 2026-02-28 | DEFRANCESCO, LISA | SVP, IR and Corp Comm | Buy | 128,190 | — | — |
| 2026-02-28 | DEFRANCESCO, LISA | SVP, IR and Corp Comm | Sale | 74,572 | $1.47 | $109620.84 |
| 2026-02-28 | DEFRANCESCO, LISA | SVP, IR and Corp Comm | Buy | 24,674 | — | — |
| 2026-02-28 | CRUM, BRIAN T | SVP, General Counsel & Secr. | Sale | 170,163 | — | — |
| 2026-02-28 | CRUM, BRIAN T | SVP, General Counsel & Secr. | Sale | 69,386 | — | — |
| 2026-02-28 | CRUM, BRIAN T | SVP, General Counsel & Secr. | Sale | 33,457 | — | — |
| 2026-02-28 | CRUM, BRIAN T | SVP, General Counsel & Secr. | Buy | 170,163 | — | — |
| 2026-02-28 | CRUM, BRIAN T | SVP, General Counsel & Secr. | Sale | 105,019 | $1.47 | $154377.93 |
| 2026-02-28 | CRUM, BRIAN T | SVP, General Counsel & Secr. | Buy | 69,386 | — | — |
| 2026-02-28 | CRUM, BRIAN T | SVP, General Counsel & Secr. | Buy | 33,457 | — | — |
| 2026-02-28 | COIANTE, SCOTT M | SVP, Chief Financial Officer | Sale | 160,237 | — | — |
| 2026-02-28 | COIANTE, SCOTT M | SVP, Chief Financial Officer | Buy | 160,237 | — | — |
| 2026-02-28 | COIANTE, SCOTT M | SVP, Chief Financial Officer | Sale | 54,881 | $1.47 | $80675.07 |
| 2026-02-25 | DEBBANE, RAYMOND | Director | Buy | 2,000 | $1.49 | $2980.00 |
| 2026-02-23 | DEBBANE, RAYMOND | Director | Buy | 100,000 | $1.47 | $147000.00 |
| 2026-02-20 | DEBBANE, RAYMOND | Director | Buy | 100,000 | $1.48 | $147790.00 |
| 2026-02-19 | DEBBANE, RAYMOND | Director | Buy | 50,000 | $1.44 | $71965.00 |
| 2026-02-18 | DEBBANE, RAYMOND | Director | Buy | 133,688 | $1.32 | $176468.16 |
| 2026-02-17 | DEBBANE, RAYMOND | Director | Buy | 76,857 | $1.31 | $100544.33 |
| 2026-02-17 | ARTAL, PARTICIPATIONS S.A R.L. | Director, 10% Owner | Buy | 41,290 | $65.00 | $2.68M |
| 2026-02-13 | DEBBANE, RAYMOND | Director | Buy | 57,952 | $1.31 | $75876.55 |
| 2026-02-12 | MCDERMOTT, WENDY | SVP, Human Resources | Buy | 375,300 | — | — |
| 2026-02-12 | MCDERMOTT, WENDY | SVP, Human Resources | Buy | 250,200 | — | — |
| 2026-02-12 | MARTENS, RACHEL YAP | SVP, Partnerships & Corp Strat | Buy | 290,620 | — | — |
| 2026-02-12 | MARTENS, RACHEL YAP | SVP, Partnerships & Corp Strat | Buy | 193,740 | — | — |
| 2026-02-12 | GRANOWITZ, CRAIG B | SVP, Chief Medical Officer | Buy | 519,920 | — | — |
| 2026-02-12 | GRANOWITZ, CRAIG B | SVP, Chief Medical Officer | Buy | 346,610 | — | — |
| 2026-02-12 | GOPINATHAN, SUMA | SVP, Discovery | Buy | 357,680 | — | — |
| 2026-02-12 | GOPINATHAN, SUMA | SVP, Discovery | Buy | 238,450 | — | — |
| 2026-02-12 | EXTON, MICHAEL | Director, Chief Executive Officer | Buy | 1,293,670 | — | — |
| 2026-02-12 | EXTON, MICHAEL | Director, Chief Executive Officer | Buy | 862,440 | — | — |
| 2026-02-12 | DEFRANCESCO, LISA | SVP, IR and Corp Comm | Buy | 386,300 | — | — |
| 2026-02-12 | DEFRANCESCO, LISA | SVP, IR and Corp Comm | Buy | 257,530 | — | — |
| 2026-02-12 | CRUM, BRIAN T | SVP, General Counsel & Secr. | Buy | 449,560 | — | — |
| 2026-02-12 | CRUM, BRIAN T | SVP, General Counsel & Secr. | Buy | 299,710 | — | — |
| 2026-02-12 | COIANTE, SCOTT M | SVP, Chief Financial Officer | Buy | 409,020 | — | — |
| 2026-02-12 | COIANTE, SCOTT M | SVP, Chief Financial Officer | Buy | 272,680 | — | — |
| 2026-02-02 | INVUS, GLOBAL MANAGEMENT, LLC | Director, 10% Owner | Buy | 367,145 | $65.00 | $23.86M |
| 2026-02-02 | INVUS, GLOBAL MANAGEMENT, LLC | Director, 10% Owner | Buy | 18,553,846 | $1.30 | $24.12M |
| 2026-02-02 | INVUS, GLOBAL MANAGEMENT, LLC | Director, 10% Owner | Buy | 3,846,154 | $1.30 | $5.00M |
| 2026-02-02 | INVUS, GLOBAL MANAGEMENT, LLC | Director, 10% Owner | Buy | 1,538,462 | $1.30 | $2.00M |
Frequently asked questions
Are LXRX insiders buying or selling?
Over the transactions on record, LXRX insiders have been net buyers, with about $994707.84 in stock sold across 32 sales, against 12 open-market purchases.
Does insider selling at LXRX mean the stock will fall?
Not by itself. Most executive selling is pre-scheduled through 10b5-1 plans filed months in advance, and insiders sell for diversification, taxes, and liquidity far more often than out of any view on the price. Insider buying is the stronger signal, especially when several insiders buy around the same time, because there is usually only one reason to put personal cash into the stock.
Which LXRX insiders are selling the most?
Recent selling is concentrated in a few names. EXTON, MICHAEL accounts for the largest share on record, with about $301101.57 sold. Selling by one or two individuals matters less than broad selling across the whole leadership team, which is the pattern worth watching.